2024-04-18  5:35:15 PM Chg. +1.15 Volume Bid5:35:15 PM Ask5:35:15 PM Market Capitalization Dividend Y. P/E Ratio
60.15EUR +1.95% 135,214
Turnover: 3.88 mill.
-Bid Size: - -Ask Size: - 11.59 bill.EUR 0.83% 20.30

Business description

Eurofins Scientific is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments. Eurofins believes it is a worldwide leader in its field. The Group offers a portfolio of more than 150,000 validated analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products. Through research and development and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
 

Management board & Supervisory board

CEO
Dr. Gilles G. Martin
Management board
Gabriel Julia, Dr. Timothy S. Oostdyk, Joachim Reichelt, Yvoine Rémy, François Vigneau, Brian Williams, Laurent Lebras, Dr. Christian Wurst, Sean Murray, Ramón Armas, Beth DiPaolo, Natalia Shuman, Gregg Tiemann
Supervisory board
Dr. Gilles Martin, Dr. Yves-Loïc Martin, Evie Roos, Fereshteh Pouchantchi, Ivo Rauh, Pascal Rakovsky, Patrizia Luchetta, Valérie Hanote
 

Company data

Name: Eurofins Scientific S.A.
Address: Chausée de Malines 455,B-1950 Kraainem
Phone: +32-2-766-1620
Fax: +32-2-766-1639
E-mail: info@eurofins.com
Internet: www.eurofins.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12-31
Free Float: 66.60%
IPO date: 1997-10-24

Investor relations

Name: -
IR phone: +32-2-769-7383
IR Fax: -
IR e-mail: ir@eurofins.com

Company calendar

CW 17 | 2024-04-24 Interim Report 1st Quarter/3 Months
CW 17 | 2024-04-25 General Shareholder Meeting
CW 30 | 2024-07-24 Interim Report 2nd Quarter/6 Months
CW 43 | 2024-10-22 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Free Floa
 
66.80%
Martin Family
 
32.70%
Treasury shares
 
0.50%